SELLAS Life Sciences (SLS) EBIAT (2020 - 2023)
Historic EBIAT for SELLAS Life Sciences (SLS) over the last 7 years, with Q4 2023 value amounting to -$8.1 million.
- SELLAS Life Sciences' EBIAT rose 1079.93% to -$8.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.3 million, marking a year-over-year increase of 958.33%. This contributed to the annual value of -$37.3 million for FY2023, which is 959.06% up from last year.
- As of Q4 2023, SELLAS Life Sciences' EBIAT stood at -$8.1 million, which was up 1079.93% from -$9.3 million recorded in Q3 2023.
- SELLAS Life Sciences' 5-year EBIAT high stood at -$2.4 million for Q1 2021, and its period low was -$16.7 million during Q1 2022.
- In the last 4 years, SELLAS Life Sciences' EBIAT had a median value of -$7.1 million in 2021 and averaged -$7.3 million.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 4199.86% in 2021, then crashed by 59679.57% in 2022.
- SELLAS Life Sciences' EBIAT (Quarter) stood at -$3.7 million in 2020, then crashed by 77.56% to -$6.6 million in 2021, then plummeted by 38.24% to -$9.1 million in 2022, then increased by 10.8% to -$8.1 million in 2023.
- Its EBIAT stands at -$8.1 million for Q4 2023, versus -$9.3 million for Q3 2023 and -$8.8 million for Q2 2023.